Engimmune Therapeutics Appoints Dr. Lars Nieba As Chief Executive Officer

Company

Location

About

Engimmune is an immunotherapy company utilising cutting-edge methods for the development of T-cell receptor (TCR)-based immunotherapies including T cell therapies and biologics. By applying our unique protein engineering toolbox we have established and continue to develop proprietary high-throughput technology platforms enabling the discovery of highly potent and safe TCR-based cell therapies and biotherapeutics, thus covering the entire TCR discovery value chain. Operating as a platform technology and product development company, our vision is to become a globally leading provider of best-in-class TCR-based therapeutics for the treatment of serious human diseases with high unmet medical need, with a particular focus on oncology.